Physician profile
Carl Conui
NPI 1275541773
$12,451.12
in general payments reported to CMS, 2019-2025
34 companies · $2,127 in 2025
The $2,127 reported for 2025 was more than what 91% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,037 · 2020: $840 · 2021: $323 · 2022: $1,307 · 2023: $1,440 · 2024: $4,377 · 2025: $2,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,504 · Travel and Lodging: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,503.82 |
| Travel and Lodging | $1,440.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $2,384.98 | 2024 | |
| Paratek Pharmaceuticals, INC. | $2,371.65 | 2020-2025 | Nuzyra |
| Organogenesis INC. | $1,299.06 | 2019-2025 | Puraply Wound Matrix, Puraply |
| Horizon Therapeutics Plc | $1,270.11 | 2019-2023 | Krystexxa |
| Kerecis Limited | $885.26 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Amgen INC. | $867.63 | 2024-2025 | Krystexxa |
| Smith+Nephew, INC. | $745.97 | 2019-2025 | Collagenase Santyl, Regranex, Grafix Pl |
| Musculoskeletal Transplant Foundation INC. | $388.38 | 2019-2020 | |
| Averitas Pharma INC. | $334.55 | 2023-2025 | Qutenza |
| Orthofix Medical, INC. | $227.95 | 2019-2025 | Physio-Stim, Accelstim |
| Grt US Holding, INC. | $215.37 | 2022 | |
| Trilliant Surgical LLC. | $191.28 | 2019 | |
| Amniox Medical, INC. | $178.44 | 2019 | |
| Ani Pharmaceuticals, INC. | $165.03 | 2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $124.98 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $117.67 | 2019-2022 | |
| Extremity Medical | $100.00 | 2019 | |
| Nevro Corp. | $65.05 | 2022 | |
| Abbvie INC. | $62.70 | 2022 | |
| Medtronic, INC. | $59.23 | 2022-2024 | Intellis Adaptivestim |
| Acumed LLC | $48.67 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $44.19 | 2019 | |
| Dynasplint Systems INC. | $39.71 | 2022 | |
| Boston Scientific Corporation | $39.62 | 2024 | |
| Integra Lifesciences Corporation | $38.45 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Misonix INC | $30.89 | 2019-2021 | |
| Sebela Pharmaceuticals INC. | $24.88 | 2023 | Naftin |
| Urgo Medical North America, LLC | $21.71 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
| Medartis INC. | $20.95 | 2019 | |
| Stryker Corporation | $20.13 | 2022 | |
| Emergent Biosolutions INC. | $18.75 | 2019 | |
| Bioventus LLC | $17.32 | 2024 | Exogen Ultrasound Bone Healing System |
| Alfasigma USA, INC. | $16.93 | 2021 | |
| Advanced Oxygen Therapy INC. | $13.63 | 2023 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Conui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.